The United States Senate Committee of Finance released their report titled "Deceptive Marketing Practices Flourish in Medicare Advantage" and excerpts from...
PAYER BARRIERS LIMIT TIMELY ACCESS Authored by Aurinia Pharma U.S., Inc. Timely access to therapy can be difficult to achieve....
The SAPHNELO Policy Acumen Portal provides up-to-date resources for billing, coding, and coverage policies specific to preselected payers. The link...
Deciding to start a blog comes with many questions and requires a lot of thought. During this process, one of...
Access Full Article from Reuters - Here
UPDATE! New Permanent J Code for SAPHNELO (anifrolumab-fnia) injection, for intravenous use, 300 mg/2mL The Centers for Medicare and Medicaid...
Wait times are a small part of each patient’s overall experience but can be a significant concern the longer they...
Authored by Aurinia Pharma U.S., Inc.Lupus nephritis (LN), a common and serious complication of systemic lupus erythematosus (SLE), occurs when...
This article on ASP recalculation for self-admin drugs will give you an understanding of how and why this change came...
New BlueCross program could change infusion billing as we know it A new program being touted by BlueCrossBlueShield of Tennessee...